This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/russia/531712-sputnik-politics-ema-who/

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
‘Politics’ prevents highly-effective Sputnik V’s approval by WHO & European regulator – leading Australian epidemiologist to RT ‘Politics’ prevents highly-effective Sputnik V’s approval by WHO & European regulator – leading Australian epidemiologist to RT
(about 2 months later)
It’s important for people in the West to know that the Russian-made Sputnik V coronavirus vaccine works great, but politics prevents it from hitting wider markets, a renowned Australian epidemiologist told RT.It’s important for people in the West to know that the Russian-made Sputnik V coronavirus vaccine works great, but politics prevents it from hitting wider markets, a renowned Australian epidemiologist told RT.
Mike Toole, a leading epidemiologist at the Melbourne-based Burnet Institute, told RT it is not exactly clear why the World Health Organization and the EU regulator, the European Medicines Agency (EMA), have not yet authorized Sputnik V for emergency use.Mike Toole, a leading epidemiologist at the Melbourne-based Burnet Institute, told RT it is not exactly clear why the World Health Organization and the EU regulator, the European Medicines Agency (EMA), have not yet authorized Sputnik V for emergency use.
Toole suggested that while the EMA may be concerned whether there has been proper monitoring of the side effects, other factors are at play as well. “Definitely, there are politics,” he said.Toole suggested that while the EMA may be concerned whether there has been proper monitoring of the side effects, other factors are at play as well. “Definitely, there are politics,” he said.
“It was developed by an excellent, world-renowned research institute – the Gamaleya, which I have visited in 1991.”“It was developed by an excellent, world-renowned research institute – the Gamaleya, which I have visited in 1991.”
Toole cited the results of clinical trials published in one of the world’s most reputable peer-reviewed medical journals, the Lancet, in February, which showed that the Russian-made vaccine has an efficacy rate close to 92%, and is 100% effective against severe cases of Covid-19.Toole cited the results of clinical trials published in one of the world’s most reputable peer-reviewed medical journals, the Lancet, in February, which showed that the Russian-made vaccine has an efficacy rate close to 92%, and is 100% effective against severe cases of Covid-19.
Sputnik V functions somewhat similarly to the vaccines made by AstraZeneca/Oxford and Johnson & Johnson (J&J) but, unlike them, does not cause side effects like blood clotting.Sputnik V functions somewhat similarly to the vaccines made by AstraZeneca/Oxford and Johnson & Johnson (J&J) but, unlike them, does not cause side effects like blood clotting.
“The reason it might not have these blood clotting events is that the vaccine has two different adenoviruses [instead of one], which kind of ‘piggy-backs’ strands of protein from the Covid virus,” Toole explained.“The reason it might not have these blood clotting events is that the vaccine has two different adenoviruses [instead of one], which kind of ‘piggy-backs’ strands of protein from the Covid virus,” Toole explained.
The EMA said earlier this year that cases of blood clotting linked to the AstraZeneca and J&J vaccines are extremely rare, and the benefits of taking them vastly outweigh the risk of dying from the coronavirus.The EMA said earlier this year that cases of blood clotting linked to the AstraZeneca and J&J vaccines are extremely rare, and the benefits of taking them vastly outweigh the risk of dying from the coronavirus.
The European regulator announced the start of a rolling review of Sputnik V in March, but has since stayed silent on the matter. Reuters quoted sources in July as saying the approval process was being delayed because Moscow had failed to provide enough data on the clinical trials.The European regulator announced the start of a rolling review of Sputnik V in March, but has since stayed silent on the matter. Reuters quoted sources in July as saying the approval process was being delayed because Moscow had failed to provide enough data on the clinical trials.
The state-run Russian Direct Investment Fund, which funded the development of Sputnik V, said the Reuters report contained “false and inaccurate statements.” The fund’s CEO, Kirill Dmitriev, has repeatedly claimed that there is political bias against the Russian vaccine, and the Western “big pharma lobby” has worked to bar it from the European market.The state-run Russian Direct Investment Fund, which funded the development of Sputnik V, said the Reuters report contained “false and inaccurate statements.” The fund’s CEO, Kirill Dmitriev, has repeatedly claimed that there is political bias against the Russian vaccine, and the Western “big pharma lobby” has worked to bar it from the European market.
Created by the Moscow-based Gamaleya Research Institute, Sputnik V became the world’s first registered Covid-19 vaccine when Russia’s state regulator approved it in August 2020. The vaccine has since been authorized for emergency use in nearly 70 countries, including Argentina, Mexico, India, Hungary, and the UAE.Created by the Moscow-based Gamaleya Research Institute, Sputnik V became the world’s first registered Covid-19 vaccine when Russia’s state regulator approved it in August 2020. The vaccine has since been authorized for emergency use in nearly 70 countries, including Argentina, Mexico, India, Hungary, and the UAE.
Think your friends would be interested? Share this story!Think your friends would be interested? Share this story!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.